"Point Therapeutics, Inc. today provided preliminary results from the Company's open-label Phase 2 trial of talabostat plus gemcitabine in patients with metastatic pancreatic cancer (Stage IV) who have not received prior chemotherapy."For starters, I always look at something like this with a skeptical eye. Companies are in the business of selling themselves to investors, so you want to be critical. In this case, you need to be even more cautious because these results are preliminary, which means they will change.
"Of the 21 evaluable patients who entered the study at least six months ago, ten (48%) have survived more than six months. In addition, 31 patients are currently evaluable for tumor response. To date, three patients (9.7%) have demonstrated a clinical response to treatment, including one complete response and two partial responses. One patient with metastatic disease to the liver experienced a complete response to treatment -- defined as the complete disappearance of tumor."Clearly, the company finds this data positive and encouraging for talabostat. But in a vacuum, it's hard to tell. This is a combination study, using two drugs in patients who've not yet received any drug treatment, so I want to know how using talabostat plus gemcitabine stacks up to using gemcitabine on its own. Since this study doesn't address that question directly, I need to find some outside data on my own. The Web site of the Food and Drug Adminstration can help here. Go to the "